News
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
Announcing our $18m Series A led by investors Creandum and with participation from Peter Thiel
The funding comes from Spotify-backer Creandum, with participation from PayPal co-founder Peter Thiel and returning investors firstminute, Seedcamp, Hambro Perks, Amino Collective, Page One Ventures and Calm/Storm. Additional investment has been provided by angel investors including Nadav Rosenberg, Kaysan Nikkhah, Trevor Martin, Soraya Darabi, Andrej Steinberg, Tom Krüger and Mithi Thaya.
Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
Lindus Health wins the 2025 Fierce CRO Award for Outstanding Patient Recruitment and Retention, highlighting the innovative use of our PIC technique.
Lindus Health and CDISC Collaborate on Innovative AI Initiative to Standardize Clinical Trial Data for Accelerated Research
Explore what this partnership means and how together, we're raising the bar for data standards across the industry.
Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape
Learn more about how our Series B funding of $55 million supports our continued mission of bringing groundbreaking treatments to patients faster.
Dr. Tim Garnett, Former Chief Medical Officer of Eli Lilly, Joins Lindus Health’s Advisory Board
Welcoming our newest advisor - Dr. Tim Garnett, former CMO at Eli Lilly!
.png)
Robert S. Langer, Co-Founder of Moderna, Joins Lindus Health’s Advisory Board
We are thrilled to announce Robert S. Langer, co-founder of Moderna, has joined our advisory board.
Discussing the FDA’s latest draft guidances on 510k submissions with M. Jason Brooke, Managing Member at Brooke & Associates
M. Jason Brooke, Attorney and Managing Member at Brooke & Associates, was kind enough to stop by our virtual fireplace to discuss the FDA’s latest draft guidances on 510k submissions and share tips on how medical device companies could best navigate them.
Announcing our $18m Series A led by investors Creandum and with participation from Peter Thiel
The funding comes from Spotify-backer Creandum, with participation from PayPal co-founder Peter Thiel and returning investors firstminute, Seedcamp, Hambro Perks, Amino Collective, Page One Ventures and Calm/Storm. Additional investment has been provided by angel investors including Nadav Rosenberg, Kaysan Nikkhah, Trevor Martin, Soraya Darabi, Andrej Steinberg, Tom Krüger and Mithi Thaya.
Improving the reliability of clinical trial data, fuelled by Innovate UK's Smart Grant
Effective clinical data management represents a fundamental part of any clinical trial, impacting safety, data integrity and the reliability of results upon which regulatory approvals are made. Through the use of AI detection models and deep learning techniques, we overcome these limitations with a product capable of real-time data capture, safety monitoring and advanced data analytics - fuelled by Innovate UK's Smart Grant.
%2520(1).png)
A Fireside Chat with Alex Zhavoronkov, founder of Insilico Medicine, on life, death and ageing
Longevity and the halt of decline may sound like the stuff of dreams that many chase in expensive face creams. But not for Alex Zhavoronkov, a spearhead in ageing and longevity and founder of Insilico Medicine. Read our fireside chat here to learn about Alex's pioneering work in this field.